Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 10/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.84 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.84 |
| ▸ | HTT | P42858 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | STK39 | Q9UEW8 | 8/20 | 0.71 |
| ▸ | PARG | Q86W56 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rafoxanide SCHEMBL118031 | 0.91 | PNLIP (1.00) | PNLIPMEN1HSPD1PIK3CAHTT | |
| Rafoxanide SCHEMBL29422184 | 0.91 | PNLIP (1.00) | PNLIPMEN1HSPD1PIK3CAHTT | |
| SCHEMBL20413308 | 0.89 | PNLIP (0.84) | PNLIPMEN1HSPD1PIK3CAHTT | |
| SCHEMBL21579434 | 0.89 | PNLIP (0.84) | PNLIPMEN1HSPD1PIK3CAHTT | |
| SCHEMBL13818501 | 0.86 | PNLIP (0.69) | PNLIPMEN1HSPD1PIK3CAHTT | |
| SCHEMBL20844337 | 0.82 | PNLIP (0.84) | PNLIPMEN1HSPD1PIK3CAHTT | |
| Rafoxanide SCHEMBL5310526 | 0.81 | PNLIP (0.79) | PNLIPMEN1HSPD1PIK3CAHTT | |
| SCHEMBL23685897 | 0.81 | PNLIP (0.80) | PNLIPMEN1HSPD1PIK3CAHTT | |
| SCHEMBL22475377 | 0.81 | PNLIP (0.80) | PNLIPMEN1HSPD1PIK3CAHTT | |
| Rafoxanide SCHEMBL22362599 | 0.79 | PNLIP (0.75) | PNLIPMEN1HSPD1PIK3CAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190350891-A1 | METHODS FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350891-A1 | METHODS FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS | FABP2, COX15, SI | PNLIP 353/4885MEN1 4569/4885HSPD1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.